A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease.

@article{Mcgregor2008AMC,
  title={A multi-center, comparative, phase 3 study to determine the efficacy of gadofosveset-enhanced magnetic resonance angiography for evaluation of renal artery disease.},
  author={Rob Roy Mcgregor and Josef Vymazal and Mar{\'i}a {\'A}ngeles Mart{\'i}nez-L{\'o}pez and Jir{\'i} Neuwirth and Perla M Salgado and Jean-Paul Beregi and Anthony Peduto and Erasmo de la Pe{\~n}a-Almaguer and Greg J. Slater and Kohkan Shamsi and Edward C. Parsons},
  journal={European journal of radiology},
  year={2008},
  volume={65 2},
  pages={
          316-25
        }
}
PURPOSE To determine prospectively the safety and efficacy of the blood-pool contrast agent gadofosveset trisodium in renal artery magnetic resonance angiography (MRA). MATERIALS AND METHODS Gadofosveset (0.03 mmol/kg) was administered to adult patients with known or suspected renal arterial disease in a multi-center phase 3 single dose study. The drug binds reversibly to albumin, prolonging the blood residence time, and allowing collection of images in the first-pass and steady-state phases… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…